Status:
UNKNOWN
Study of Metastatic Ocular Melanoma
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Ocular Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
Detailed Description
Treatment of patients with metastatic ocular melanoma with combination chemotherapy Gemcitabine and Treosulfan versus monotherapy with Treosulfan as first-line chemotherapy.
Eligibility Criteria
Inclusion
- Metastatic ocular melanoma
Exclusion
- Prior treatment with chemotherapy
- Active 2nd malignancy
- Cerebral metastasis
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00168870
Start Date
February 1 2003
Last Update
August 31 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology & Oncology Charité CBF Berlin
Berlin, State of Berlin, Germany, 12203